AAAAAA

   
Results: 1-7 |
Results: 7
TREATMENT OF ESTABLISHED POSTMENOPAUSAL OSTEOPOROSIS WITH RALOXIFENE - A RANDOMIZED
Authors: LUFKIN EG WHITAKER MD NICKELSEN T ARGUETA R CAPLAN RH KNICKERBOCKER RK RIGGS BL
Citation: Eg. Lufkin et al., TREATMENT OF ESTABLISHED POSTMENOPAUSAL OSTEOPOROSIS WITH RALOXIFENE - A RANDOMIZED, Journal of bone and mineral research, 13(11), 1998, pp. 1747-1754
RALOXIFENE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
Authors: LUFKIN EG WHITAKER MD ARGUETA R CAPLAN RH NICKELSEN T RIGGS BL
Citation: Eg. Lufkin et al., RALOXIFENE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS, Journal of bone and mineral research, 12, 1997, pp. 191-191
3-YEAR FOLLOW-UP ON EFFECTS OF TRANSDERMAL ESTROGEN
Authors: LUFKIN EG RIGGS BL
Citation: Eg. Lufkin et Bl. Riggs, 3-YEAR FOLLOW-UP ON EFFECTS OF TRANSDERMAL ESTROGEN, Annals of internal medicine, 125(1), 1996, pp. 77-77
POSTMENOPAUSAL ESTROGEN THERAPY, 1995
Authors: LUFKIN EG ORY SJ
Citation: Eg. Lufkin et Sj. Ory, POSTMENOPAUSAL ESTROGEN THERAPY, 1995, Trends in endocrinology and metabolism, 6(2), 1995, pp. 50-54
EPIDEMIOLOGY AND CLINICAL-FEATURES OF OSTEOPOROSIS IN YOUNG INDIVIDUALS
Authors: KHOSLA S LUFKIN EG HODGSON SF FITZPATRICK LA MELTON LJ
Citation: S. Khosla et al., EPIDEMIOLOGY AND CLINICAL-FEATURES OF OSTEOPOROSIS IN YOUNG INDIVIDUALS, Bone, 15(5), 1994, pp. 551-555
PAMIDRONATE - AN UNRECOGNIZED PROBLEM IN GASTROINTESTINAL TOLERABILITY
Authors: LUFKIN EG ARGUETA R WHITAKER MD CAMERON AL WONG VH EGAN KS OFALLON WM RIGGS BL
Citation: Eg. Lufkin et al., PAMIDRONATE - AN UNRECOGNIZED PROBLEM IN GASTROINTESTINAL TOLERABILITY, Osteoporosis international, 4(6), 1994, pp. 320-322
RELATIVE VALUE OF TRANSDERMAL AND ORAL ESTROGEN THERAPY IN VARIOUS CLINICAL SITUATIONS
Authors: LUFKIN EG ORY SJ
Citation: Eg. Lufkin et Sj. Ory, RELATIVE VALUE OF TRANSDERMAL AND ORAL ESTROGEN THERAPY IN VARIOUS CLINICAL SITUATIONS, Mayo Clinic proceedings, 69(2), 1994, pp. 131-135
Risultati: 1-7 |